PE33396A1 - COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS - Google Patents

COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS

Info

Publication number
PE33396A1
PE33396A1 PE1995272088A PE27208895A PE33396A1 PE 33396 A1 PE33396 A1 PE 33396A1 PE 1995272088 A PE1995272088 A PE 1995272088A PE 27208895 A PE27208895 A PE 27208895A PE 33396 A1 PE33396 A1 PE 33396A1
Authority
PE
Peru
Prior art keywords
nicotine
composition
ansia
smoking
symptoms
Prior art date
Application number
PE1995272088A
Other languages
Spanish (es)
Inventor
Satyanarayana Majeti
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE33396A1 publication Critical patent/PE33396A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

CARACTERIZADA POR SER LIQUIDA QUE COMPRENDE NICOTINA Y CAFEINA, EN DONDE LA COMPOSICION SUMINISTRA: A) DESDE 0,01 mg A 2 mg DE NICOTINA; B) DESDE 3 mg A 20 mg DE CAFEINA; C) UNO O MAS VEHICULOS FARMACEUTICOS ACEPTABLES; D) DESDE 0,5% A 10% DE UN AGENTE TENSIOACTIVO FARMACEUTICAMENTE ACEPTABLE; E) DESDE 0,001% A 2% DE UN AGENTE DE CONSERVACION FARMACEUTICAMENTE ACEPTABLE; F) DESDE 0,01% A 5% DE UN HUMECTANTE ACEPTABLE. LA SOLUCION SE ENCUENTRA EN FORMA DE UNA SOLUCION SALINA ACUOSA QUE COMPRENDE DESDE 0,5% A 1% DE CLORURO DE SODIO Y DESDE 95% A 99,5% DE AGUA PURIFICADACHARACTERIZED AS A LIQUID THAT INCLUDES NICOTINE AND CAFFEINE, WHERE THE COMPOSITION PROVIDES: A) FROM 0.01 mg TO 2 mg OF NICOTINE; B) FROM 3 mg TO 20 mg OF CAFFEINE; C) ONE OR MORE ACCEPTABLE PHARMACEUTICAL VEHICLES; D) FROM 0.5% TO 10% OF A PHARMACEUTICALLY ACCEPTABLE SURFACE AGENT; E) FROM 0.001% TO 2% OF A PHARMACEUTICALLY ACCEPTABLE CONSERVATION AGENT; F) FROM 0.01% TO 5% OF AN ACCEPTABLE MOISTURIZER. THE SOLUTION IS IN THE FORM OF AN AQUEOUS SALT SOLUTION, INCLUDING FROM 0.5% TO 1% SODIUM CHLORIDE AND FROM 95% TO 99.5% PURIFIED WATER

PE1995272088A 1994-06-23 1995-06-22 COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS PE33396A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26426294A 1994-06-23 1994-06-23

Publications (1)

Publication Number Publication Date
PE33396A1 true PE33396A1 (en) 1996-08-19

Family

ID=23005260

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995272088A PE33396A1 (en) 1994-06-23 1995-06-22 COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS

Country Status (6)

Country Link
AU (1) AU2703695A (en)
IL (1) IL114129A0 (en)
MA (1) MA23588A1 (en)
PE (1) PE33396A1 (en)
WO (1) WO1996000071A1 (en)
ZA (1) ZA955032B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO108596A0 (en) * 1996-07-18 1996-08-08 Collier, Gregory Treatment of obesity
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7078016B2 (en) 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US20110053988A1 (en) * 2009-08-29 2011-03-03 Jorge Alberto Cassara Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke
DE102011114094A1 (en) * 2011-09-21 2013-03-21 F. Holzer Gmbh Stimulating and invigorating nasal spray and nose drops
NZ744942A (en) * 2016-04-12 2020-08-28 Herrera Arturo Solis Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
US20210161986A1 (en) * 2018-04-16 2021-06-03 Barista Mist Pty Ltd Caffeine compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778677A (en) * 1981-07-09 1988-10-18 Ebbesen Gerald K Method for treatment of nicotine craving
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
DE3506406A1 (en) * 1985-02-23 1986-08-28 Hans-Josef 5600 Wuppertal Stromberg DEVICE FOR THE DEWNING OF EATING, DRINKING, SMOKING AND / OR ADDICTIVE Habits
US5051426A (en) * 1990-03-27 1991-09-24 Parnell Pharmaceuticals, Inc. Method for effecting withdrawal from drug dependency

Also Published As

Publication number Publication date
IL114129A0 (en) 1995-10-31
MA23588A1 (en) 1995-12-31
ZA955032B (en) 1996-03-11
AU2703695A (en) 1996-01-19
WO1996000071A1 (en) 1996-01-04

Similar Documents

Publication Publication Date Title
UY25374A1 (en) APOMORPHINE COMPOSITIONS USEFUL IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION
RU94041223A (en) Agent for motoneuron disease treatment
SE8903914D0 (en) ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES
ATE113834T1 (en) COMPOSITION FOR THE TREATMENT OF SCHIZOPHRENIA.
ES2167453T3 (en) MEDICINAL SUPPLY COMPOSITION CONTAINING CHITOSANE OR DERIVATIVE OF THE SAME WITH A POTENTIAL Z. DEFINED.
KR970704429A (en) USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
DE3851152D1 (en) CYCLOSPORINE EYE PRODUCTS.
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
AR020803A1 (en) A COMPOSITION THAT INCLUDES FEXOFENADINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINE
PE33396A1 (en) COMPOSITION FOR THE TREATMENT OF NICOTINE ANSIA AND / OR ABSTRACT SMOKING SYMPTOMS
PE68899A1 (en) COMPOSITION CONTAINING PARACETAMOL
ES8305363A1 (en) Topical formulations of 9-(2-hydroxyethoxymethyl) guanine.
AR015744A1 (en) USE OF DEXMEDETOMIDINE FOR SEDATION IN INTENSIVE THERAPY
MX9205568A (en) PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE.
ES2142430T3 (en) PHARMACEUTICAL COMPOUNDS IN THE FORM OF GEL CONTAINING SALTS OF CHONDROITIN SULPHATE SUITABLE FOR ORAL ADMINISTRATION.
CO4960654A1 (en) METHOD FOR THE TREATMENT OF PHYSIOLOGICAL DISEASES RELATED TO THE USE OR SEQUELS CAUSED BY THE USE OF COCAINE OR OTHER PSYCHOMOTOR STIMULANTS
BR0111325A (en) process of controlling snoring in a person, and product adapted for use in treating snoring
ES2039433T3 (en) A PHARMACEUTICAL FORMULATION.
ATE81462T1 (en) GLYCOSAMINOGLYCAN FOR THE TREATMENT OF DIABETIC MICROANGIOPATHIA.
KR920702225A (en) Pharmaceutical composition
KR920014474A (en) Preparations for Gallstone Collapse
ES2092559T3 (en) PHARMACEUTICAL FORMULATION CONTAINING PENCICLOVIR.
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
ES2128353T3 (en) TOPIC COMPOSITION CONTAINING PENCICLOVIR.
AR044697A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE AMOXYCLINE AND CLAVULANATE

Legal Events

Date Code Title Description
FD Application declared void or lapsed